Bruzzone Bianca, Saladini Francesco, Sticchi Laura, Mayinda Mboungou Franc A, Barresi Renata, Caligiuri Patrizia, Calzi Anna, Zazzi Maurizio, Icardi Giancarlo, Viscoli Claudio, Bisio Francesca
1 Hygiene Unit, IRCCS AOU San Martino-IST , Genoa, Italy .
2 Department of Medical Biotechnologies, University of Siena , Siena, Italy .
AIDS Res Hum Retroviruses. 2015 Aug;31(8):837-40. doi: 10.1089/AID.2015.0105. Epub 2015 Jun 2.
The Kento-Mwana project was carried out in Pointe Noire, Republic of the Congo, to prevent mother-to-child HIV-1 transmission. To determine the prevalence of different subtypes and transmitted drug resistance-associated mutations, 95 plasma samples were collected at baseline from HIV-1-positive naive pregnant women enrolled in the project during the years 2005-2008. Full protease and partial reverse transcriptase sequencing was performed and 68/95 (71.6%) samples were successfully sequenced. Major mutations to nucleoside reverse transcriptase inhibitors, nonnucleoside reverse transcriptase inhibitors, and protease inhibitors were detected in 4/68 (5.9%), 3/68 (4.4%), and 2/68 (2.9%) samples, respectively. Phylogenetic analysis of HIV-1 isolates showed a high prevalence of unique recombinant forms (24/68, 35%), followed by CRF45_cpx (7/68, 10.3%) and subsubtype A3 and subtype G (6/68 each, 8.8%). Although the prevalence of transmitted drug resistance mutations appears to be currently limited, baseline HIV-1 genotyping is highly advisable in conjunction with antiretroviral therapy scale-up in resource-limited settings to optimize treatment and prevent perinatal transmission.
“肯托-姆瓦纳”项目在刚果共和国黑角市开展,旨在预防母婴传播HIV-1。为确定不同亚型和传播性耐药相关突变的流行情况,2005年至2008年期间,从参与该项目的HIV-1阳性初治孕妇中,在基线时收集了95份血浆样本。进行了完整蛋白酶和部分逆转录酶测序,68/95(71.6%)份样本成功测序。分别在4/68(5.9%)、3/68(4.4%)和2/68(2.9%)份样本中检测到对核苷类逆转录酶抑制剂、非核苷类逆转录酶抑制剂和蛋白酶抑制剂的主要突变。对HIV-1分离株的系统发育分析显示,独特重组形式的流行率很高(24/68,35%),其次是CRF45_cpx(7/68,10.3%)以及A3亚亚型和G亚型(各6/68,8.8%)。虽然目前传播性耐药突变的流行率似乎有限,但在资源有限的环境中扩大抗逆转录病毒治疗规模时,强烈建议进行基线HIV-1基因分型,以优化治疗并预防围产期传播。